Emerging tocolytics: challenges in designing and testing drugs to delay preterm delivery and prolong pregnancy

Bibliography

• Mathews TJ, Menacker F, MacDorman MF. Infant mortality statistics from the 2002 period: linked birth/infant death data set. Natl Vital Stat Rep 2004;53:1-29
   PubMedGoogle Scholar
• Gray RF, Indurkhya A, McCormick MC. Prevalence, stability, and predictors of clinically significant behavior problems in low birth weight children at 3, 5, and 8 years of age. Pediatrics 2004;114:736-43
   PubMed Web of Science ®Google Scholar
• Hack M, Flannery DJ, Schluchter M, et al. Outcomes in young adulthood for very-low-birth-weight infants. N Engl J Med 2002;346:149-57
   PubMed Web of Science ®Google Scholar
• McCormick MC, Richardson DK. Premature infants grow up. N Engl J Med 2002;346:197-8
   PubMed Web of Science ®Google Scholar
• Goldenberg RL, Rouse DJ. Prevention of premature birth. N Engl J Med 1998;339:313-20
   PubMed Web of Science ®Google Scholar
• Allen MC, Donohue PK, Dusman AE. The limit of viability–neonatal outcome of infants born at 22 to 25 weeks' gestation. N Engl J Med 1993;329:1597-601
   PubMed Web of Science ®Google Scholar
• Lefebvre F, Glorieux J, St-Laurent-Gagnon T. Neonatal survival and disability rate at age 18 months for infants born between 23 and 28 weeks of gestation. Am J Obstet Gynecol 1996;174:833-8
   PubMed Web of Science ®Google Scholar
• O'Shea TM, Klinepeter KL, Goldstein DJ, et al. Survival and developmental disability in infants with birth weights of 501 to 800 grams, born between 1979 and 1994. Pediatrics 1997;100:982-6
   PubMed Web of Science ®Google Scholar
• Kilpatrick SJ, Schlueter MA, Piecuch R, et al. Outcome of infants born at 24-26 weeks' gestation: I. Survival and cost. Obstet Gynecol 1997;90:803-8
   PubMed Web of Science ®Google Scholar
• Hack M, Friedman H, Fanaroff AA. Outcomes of extremely low birth weight infants. Pediatrics 1996;98:931-7
   PubMed Web of Science ®Google Scholar
• Hack M, Fanaroff AA. Outcomes of children of extremely low birthweight and gestational age in the 1990's. Early Hum Dev 1999;53:193-218
   PubMed Web of Science ®Google Scholar
• Wood NS, Marlow N, Costeloe K, et al. Neurologic and developmental disability after extremely preterm birth. EPICure Study Group. N Engl J Med 2000;343:378-84
   PubMed Web of Science ®Google Scholar
• Botting N, Powls A, Cooke RW, et al. Cognitive and educational outcome of very-low-birthweight children in early adolescence. Dev Med Child Neurol 1998;40:652-60
   PubMed Web of Science ®Google Scholar
• Buck GM, Msall ME, Schisterman EF, et al. Extreme prematurity and school outcomes. Paediatr Perinat Epidemiol 2000;14:324-31
   PubMed Web of Science ®Google Scholar
• Hall A, Mcleod A, Counsell C, et al. School attainment, cognitive ability and motor function in a total Scottish very-low-birthweight population at eight years: a controlled study. Dev Med Child Neurol 1995;37:1037-50
   PubMed Web of Science ®Google Scholar
• Saigal S, Szatmari P, Rosenbaum P, et al. Cognitive abilities and school performance of extremely low birth weight children and matched term control children at age 8 years: a regional study. J Pediatr 1991;118:751-60
   PubMed Web of Science ®Google Scholar
• Schwartz RM, Kellogg R, Muri JH. Specialty newborn care: trends and issues. J Perinatol 2000;20:520-9
   PubMedGoogle Scholar
• Wolke D, Meyer R. Cognitive status, language attainment, and prereading skills of 6-year-old very preterm children and their peers: the Bavarian Longitudinal Study. Dev Med Child Neurol 1999;41:94-109
   PubMed Web of Science ®Google Scholar
• The Scottish low birthweight study: II. Language attainment, cognitive status, and behavioural problems. Arch Dis Child 1992;67:682-6
   PubMed Web of Science ®Google Scholar
• Bhutta AT, Cleves MA, Casey PH, et al. Cognitive and behavioral outcomes of school-aged children who were born preterm: a meta-analysis. JAMA 2002;288:728-37
   PubMed Web of Science ®Google Scholar
• Botting N, Powls A, Cooke RW, et al. Attention deficit hyperactivity disorders and other psychiatric outcomes in very low birthweight children at 12 years. J Child Psychol Psychiatry 1997;38:931-41
   PubMed Web of Science ®Google Scholar
• Grunau RE, Whitfield MF, Davis C. Pattern of learning disabilities in children with extremely low birth weight and broadly average intelligence. Arch Pediatr Adolesc Med 2002;156:615-20
   PubMed Web of Science ®Google Scholar
• Horwood LJ, Mogridge N, Darlow BA. Cognitive, educational, and behavioural outcomes at 7 to 8 years in a national very low birthweight cohort. Arch Dis Child Fetal Neonatal Ed 1998;79:F12-20
   PubMed Web of Science ®Google Scholar
• Pharoah PO, Stevenson CJ, Cooke RW, et al. Prevalence of behaviour disorders in low birthweight infants. Arch Dis Child 1994;70:271-4
   PubMed Web of Science ®Google Scholar
• Engle WA. A recommendation for the definition of “late preterm” (near-term) and the birth weight-gestational age classification system. Semin Perinatol 2006;30:2-7
   PubMed Web of Science ®Google Scholar
• Sumner G, Spietz A. NCAST Caregiver/Parent-Child Interaction Teaching ManualNCAST Publications. Seattle, WA: University of Washington, School of Nursing, 1994
   Google Scholar
• Magill-Evans J, Harrison MJ, Van Der Zalm J, et al. Cognitive and language development of healthy preterm infants at 10 years of age. Phys Occup Ther Pediatr 2002;22:41-56
   PubMedGoogle Scholar
• Statistics Canada, 2004
   Google Scholar
• Outcomes CoUPBaAH. In: Preterm Birth: Causes, Consequences, and Prevention. RB, editors. The National Academies Press, Washington, DC, 2006
   Google Scholar
• Martin JA, Hamilton BE, Sutton PD, et al. Births: final data for 2003. Natl Vital Stat Rep 2005;54:1-116
   PubMedGoogle Scholar
• Paneth NS. The problem of low birth weight. Future Child 1995;5:19-34
   PubMed Web of Science ®Google Scholar
• Rogowski J. Measuring the cost of neonatal and perinatal care. Pediatrics 1999;103:329-35
   PubMedGoogle Scholar
• ST John EB, Nelson KG, Cliver SP, et al. Cost of neonatal care according to gestational age at birth and survival status. Am J Obstet Gynecol 2000;182:170-5
   PubMed Web of Science ®Google Scholar
• Berhman R, Butler A. Preterm Birth: Causes, Consequences, and Prevention. Washington, DC.: The National Academies Press, 2006
   Google Scholar
• Green NS, Damus K, Simpson JL, et al. Research agenda for preterm birth: recommendations from the March of Dimes. Am J Obstet Gynecol 2005;193:626-35
   PubMed Web of Science ®Google Scholar
• Cunningham F, Leveno K, Bloom S, et al. Phases of Parturition. In: Williams Obstetrics. McGraw-Hill, editors; 2005
   Google Scholar
• Olson DM, Mijovic JE, Sadowsky DW. Control of human parturition. Semin Perinatol 1995;19:52-63
   PubMed Web of Science ®Google Scholar
• Challis JRG. Mechanism of parturition and preterm labor. Obstet Gynecol Surv 2000;55:650-60
   PubMed Web of Science ®Google Scholar
• Goodwin TM. The Gordian knot of developing tocolytics. J Soc Gynecol Investig 2004;11:339-41
   PubMedGoogle Scholar
• Goodwin TM. Regulatory and methodologic challenges to tocolytic development. BJOG 2006;113(Suppl 3):100-4
   PubMed Web of Science ®Google Scholar
• Olson DM. The promise of prostaglandins: have they fulfilled their potential as therapeutic targets for the delay of preterm birth? J Soc Gynecol Investig 2005;12:466-78
   PubMedGoogle Scholar
• Groom KM, Shennan AH, Jones BA, et al. TOCOX–a randomised, double-blind, placebo-controlled trial of rofecoxib (a COX-2-specific prostaglandin inhibitor) for the prevention of preterm delivery in women at high risk. BJOG 2005;112:725-30
   PubMed Web of Science ®Google Scholar
• Effectiveness and safety of the oxytocin antagonist atosiban versus beta-adrenergic agonists in the treatment of preterm labour. The Worldwide Atosiban versus Beta-agonists Study Group. BJOG 2001;108:133-42
   PubMed Web of Science ®Google Scholar
• Valenzuela GJ, Sanchez-Ramos L, Romero R, et al. Maintenance treatment of preterm labor with the oxytocin antagonist atosiban. The Atosiban PTL-098 Study Group. Am J Obstet Gynecol 2000;182:1184-90
   PubMed Web of Science ®Google Scholar
• Moutquin JM, Sherman D, Cohen H, et al. Double-blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study. Am J Obstet Gynecol 2000;182:1191-9
   PubMed Web of Science ®Google Scholar
• Available from: http://www.fda.gov/ohrms/dockets/ac/cder06.html#rhdac U.S Food and Drug Administration website FDA Advisory Committees, 2006
   Google Scholar
• Tan TC, Devendra K, Tan LK, et al. Tocolytic treatment for the management of preterm labour: a systematic review. Singapore Med J 2006;47:361-6
   PubMedGoogle Scholar
• Shim SS, Romero R, Hong JS, et al. Clinical significance of intra-amniotic inflammation in patients with preterm premature rupture of membranes. Am J Obstet Gynecol 2004;191:1339-45
   PubMed Web of Science ®Google Scholar
• Fuchs AR, Fuchs F. Ethanol for prevention of preterm birth. Semin Perinatol 1981;5:236-51
   PubMed Web of Science ®Google Scholar
• Zervoudakis IA, Krauss A, Fuchs F. Infants of mothers treated with ethanol for premature labor. Am J Obstet Gynecol 1980;137:713-8
   PubMed Web of Science ®Google Scholar
• Barden TP, Peter JB, Merkatz IR. Ritodrine hydrochloride: a betamimetic agent for use in preterm labor. I. pharmacology, clinical history, administration, side effects, and safety. Obstet Gynecol 1980;56:1-6
   PubMed Web of Science ®Google Scholar
• Anotayanonth S, Subhedar NV, Garner P, et al. Betamimetics for inhibiting preterm labour. Cochrane Database Syst Rev 2004;CD004352
   PubMedGoogle Scholar
• Di Renzo GC, Roura LC. Guidelines for the management of spontaneous preterm labor. J Perinat Med 2006;34:359-66
   PubMed Web of Science ®Google Scholar
• Clinical Guideline No.1(B): Tocolytic drugs for women in preterm labour. Royal College of Obstetricians and Gynaecologists, 2002
   Google Scholar
• Mitchell BF, Olson DM. Prostaglandin endoperoxide H synthase inhibitors and other tocolytics in preterm labour. Prostaglandins Leukot Essent Fatty Acids 2004;70:167-87
   PubMed Web of Science ®Google Scholar
• Crowther CA, Hiller JE, Doyle LW. Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database Syst Rev 2002;CD001060
   PubMedGoogle Scholar
• Manning M, Miteva K, Pancheva S, et al. Design and synthesis of highly selective in vitro and in vivo uterine receptor antagonists of oxytocin: comparisons with Atosiban. Int J Pept Protein Res 1995;46:244-52
   PubMedGoogle Scholar
• Nilsson L, Reinheimer T, Steinwall M, et al. FE 200 440: a selective oxytocin antagonist on the term-pregnant human uterus. BJOG 2003;110:1025-8
   PubMed Web of Science ®Google Scholar
• King JF. Tocolysis and preterm labour. Curr Opin Obstet Gynecol 2004;16:459-63
   PubMed Web of Science ®Google Scholar
• Romero R, Sibai BM, Sanchez-Ramos L, et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double-blind, placebo-controlled trial with tocolytic rescue. Am J Obstet Gynecol 2000;182:1173-83
   PubMed Web of Science ®Google Scholar
• Papatsonis D, Flenady V, Cole S, et al. Oxytocin receptor antagonists for inhibiting preterm labour. Cochrane Database Syst Rev 2005;CD004452
   PubMedGoogle Scholar
• Treatment of preterm labor with the oxytocin antagonist atosiban: a double-blind, randomized, controlled comparison with salbutamol. Eur J Obstet Gynecol Reprod Biol 2001;98:177-85
   PubMed Web of Science ®Google Scholar
• Reinheimer TM, Bee WH, Resendez JC, et al. Barusiban, a new highly potent and long-acting oxytocin antagonist: pharmacokinetic and pharmacodynamic comparison with atosiban in a cynomolgus monkey model of preterm labor. J Clin Endocrinol Metab 2005;90:2275-81
   PubMed Web of Science ®Google Scholar
• Reinheimer TM, Chellman GJ, Resendez JC, et al. Barusiban, an effective long-term treatment of oxytocin-induced preterm labor in nonhuman primates. Biol Reprod 2006;75:809-14
   PubMed Web of Science ®Google Scholar
• Thornton S, Goodwin T, Greisen G, et al. The effect of a selective oxytocin antagonist (barusiban) in threatened preterm labour: A randomised, double-blind, placebo-controlled trial. Reproductive Sciences 2008;15:S97A
   Google Scholar
• Lamont R, Van Eyck J. Tocolysis with nifedipine or beta-adrenergic agonists: a meta-analysis. Obstet Gynecol 2002;99:518-9;author reply 519-520
   Google Scholar
• King JF, Flenady VJ, Papatsonis DN, et al. Calcium channel blockers for inhibiting preterm labour. Cochrane Database Syst Rev 2002;CD002255
   Google Scholar
• Smith GN, Walker MC, Mcgrath MJ. Randomised, double-blind, placebo controlled pilot study assessing nitroglycerin as a tocolytic. Br J Obstet Gynaecol 1999;106:736-9
   PubMedGoogle Scholar
• Buhimschi CS, Buhimschi IA, Malinow AM, et al. Effects of sublingual nitroglycerin on human uterine contractility during the active phase of labor. Am J Obstet Gynecol 2002;187:235-8
   PubMed Web of Science ®Google Scholar
• Duckitt K, Thornton S. Nitric oxide donors for the treatment of preterm labour. Cochrane Database Syst Rev 2002;CD002860
   Google Scholar
• King J, Flenady V, Cole S, et al. Cyclo-oxygenase (COX) inhibitors for treating preterm labour. Cochrane Database Syst Rev 2005;CD001992
   Google Scholar
• Hui D, Liu G, Kavuma E, et al. Preterm labour and birth: a survey of clinical practice regarding use of tocolytics, antenatal corticosteroids, and progesterone. J Obstet Gynaecol Can 2007;29:117-30
   PubMedGoogle Scholar
• Zaragoza DB, Wilson RR, Mitchell BF, et al. The interleukin 1beta-induced expression of human prostaglandin F2alpha receptor messenger RNA in human myometrial-derived ULTR cells requires the transcription factor, NFkappaB. Biol Reprod 2006;75:697-704
   PubMed Web of Science ®Google Scholar
• Hirst JJ, Parkington HC, Young IR, et al. Delay of preterm birth in sheep by THG113.31, a prostaglandin F2alpha receptor antagonist. Am J Obstet Gynecol 2005;193:256-66
   PubMed Web of Science ®Google Scholar
• Di Renzo GC, Rosati A, Mattei A, et al. The changing role of progesterone in preterm labour. BJOG 2005;112(Suppl 1):57-60
   PubMed Web of Science ®Google Scholar
• Mitchell BF, Mitchell JM, Chowdhury J, et al. Metabolites of progesterone and the pregnane X receptor: a novel pathway regulating uterine contractility in pregnancy? Am J Obstet Gynecol 2005;192:1304-13;discussion 1313-1305
   PubMed Web of Science ®Google Scholar
• Farine D, Mundle WR, Dodd J, et al. The use of progesterone for prevention of preterm birth. J Obstet Gynaecol Can 2008;30:67-77
   PubMedGoogle Scholar
• Meis PJ, Klebanoff M, Thom E, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003;348:2379-85
   PubMed Web of Science ®Google Scholar
• Petrini JR, Callaghan WM, Klebanoff, et al. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States. Obstet Gynecol 2005;105:267-72
   PubMed Web of Science ®Google Scholar
• Defranco EA, O'brien JM, Adair CD, et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2007;30:697-705
   PubMed Web of Science ®Google Scholar
• Fonseca EB, Celik E, Parra M, et al. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med 2007;357:462-9
   PubMed Web of Science ®Google Scholar
• Dodd JM, Flenady V, Cincotta R, et al. Prenatal administration of progesterone for preventing preterm birth. Cochrane Database Syst Rev 2006;CD004947
   Google Scholar
• Rouse DJ, Caritis SN, Peaceman AM, et. al. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med 2007;357:454-61
   PubMed Web of Science ®Google Scholar
• Lim AC, Bloemenkamp KW, Boer K, et al. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. BMC Pregnancy Childbirth 2007;7:7
   PubMedGoogle Scholar
• Hertelendy F, Molnar M, Romero R. Interferon gamma antagonizes interleukin-1beta-induced cyclooxygenase-2 expression and prostaglandin E2; production in human myometrial cells. J Soc Gynecol Investig 2002;9:215-9
   PubMedGoogle Scholar
• Kniss DA, Rovin B, Fertel RH, et al. Blockade NF-kappaB activation prohibits TNF-alpha-induced cyclooxygenase-2 gene expression in ED27 trophoblast-like cells. Placenta 2001;22:80-9
   PubMed Web of Science ®Google Scholar
• Belt AR, Baldassare JJ, Molnar M, et al. The nuclear transcription factor NF-kappaB mediates interleukin-1beta-induced expression of cyclooxygenase-2 in human myometrial cells. Am J Obstet Gynecol 1999;181:359-66
   PubMed Web of Science ®Google Scholar
• Lappas M, Yee K, Permezel M, et al. Lipopolysaccharide and TNF-alpha activate the nuclear factor kappa B pathway in the human placental JEG-3 cells. Placenta 2006;27:568-75
   PubMed Web of Science ®Google Scholar
• Allport VC, Pieber D, Slater DM, et al. Human labour is associated with nuclear factor-kappaB activity which mediates cyclo-oxygenase-2 expression and is involved with the ‘functional progesterone withdrawal’. Mol Hum Reprod 2001;7:581-6
   PubMed Web of Science ®Google Scholar
• Zaragoza DB, Wilson R, Eyster K, et al. Cloning and characterization of the promoter region of the human prostaglandin F2alpha receptor gene. Biochim Biophys Acta 2004;1676:193-202
   PubMed Web of Science ®Google Scholar
• Condon JC, Jeyasuria P, Faust JM, et al. Surfactant protein secreted by the maturing mouse fetal lung acts as a hormone that signals the initiation of parturition. Proc Natl Acad Sci USA 2004;101:4978-83
   PubMed Web of Science ®Google Scholar
• Peri KG, Quiniou C, Hou X, et al. THG113: a novel selective FP antagonist that delays preterm labor. Semin Perinatol 2002;26:389-97
   PubMed Web of Science ®Google Scholar
• Balachandra S, Genovese T, Mazzon E, et al. Inhibition of tyrosine-kinase-mediated cellular signaling by tyrphostins AG 126 and AG556 modulates murine experimental acute pancreatitis. Surgery 2005;138:913-23
   PubMed Web of Science ®Google Scholar
• Shouda T, Hiraoka K, Komiya S, et al. Suppression of IL-6 production and proliferation by blocking STAT3 activation in malignant soft tissue tumor cells. Cancer Lett 2006;231:176-84
   PubMed Web of Science ®Google Scholar
• Zakar T, Mijovic JE, Bhardwaj D, et al. Tyrosine kinase inhibitors block the glucocorticoid stimulation of prostaglandin endoperoxide H synthase expression in amnion cells. Can J Physiol Pharmacol 1999;77:138-42
   PubMed Web of Science ®Google Scholar
• Mijovic JE, Zakar T, Zaragoza DB, et al. Tyrphostins inhibit lipopolysaccharide induced preterm labor in mice. J Perinat Med 2002;30:297-300
   PubMed Web of Science ®Google Scholar
• Prasit P, Wang Z, Brideau C, et al. The discovery of rofecoxib, [MK 966, Vioxx, 4-(4′-methylsulfonylphenyl)- 3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. Bioorg Med Chem Lett 1999;9:1773-8
   PubMed Web of Science ®Google Scholar